A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC.

A Lisberg,A Cummings,J W Goldman,K Bornazyan,N Reese,T Wang,P Coluzzi,B Ledezma,M Mendenhall,J Hunt, B Wolf,B Jones,J Madrigal, J Horton,M Spiegel,J Carroll,J Gukasyan,T Williams, L Sauer, C Wells, A Hardy, P Linares, C Lim, L Ma, C Adame,Edward B Garon

Journal of Thoracic Oncology（2018）

引用 419|浏览22

暂无评分

摘要

Pembrolizumab's lack of efficacy in TKI naïve, PD-L1+, EGFR-mutant patients with advanced NSCLC, including those with PD-L1 expression >50%, suggests that it is not an appropriate therapeutic choice in this setting.

查看译文

关键词

NSCLC,programmed death 1 (PD-1),EGFR,tumor immunology,pembrolizumab,programmed death ligand 1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要